Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China

• 主要な著者: Hao Wang (著者), Ye Wang (著者), Li Li (著者), Han Zhou (著者), Shang Lili (著者), Liao Li (著者), Shen Yike (著者), Ma Aixia (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

BackgroundIn the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib (NI + CA) has shown efficacy for advanced renal cell carcinoma. This study aims to evaluate the impact of the health and economic outcomes of NI + CA in China.MethodsClinical efficacy data were derive...